Evidence map›Paper›PMID 24687050›Full record

ArticleNature reviews. Drug discovery2014

Integrative knowledge management to enhance pharmaceutical R&D.

Maria Marti-Solano, Ewan Birney, Antoine Bril, Oscar Della Pasqua, Hiroaki Kitano, Barend Mons, Ioannis Xenarios, Ferran Sanz

Abstract read
PubMed Publisher
In one paragraph

Article in Nature reviews. Drug discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria Marti-SolanoIMIM and Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain.
Ewan BirneyEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridgeshire CB10 1SD, UK.
Antoine BrilInstitut de Recherches Internationales Servier, 53 rue Carnot, 92284 Suresnes Cedex, France.
Oscar Della PasquaGlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK.
Hiroaki KitanoSystems Biology Institute, 5-6-9 Shirokanedai, Minato, Tokyo 108-0071, Japan; and the RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan.
Barend MonsNetherlands Bioinformatics Centre, 260 NBIC, 6500 HB Nijmegen, The Netherlands; and the Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Ioannis XenariosSwiss Institute of Bioinformatics, Quartier Sorge - Batiment Genopode, 1015 Lausanne, Switzerland.
Ferran SanzIMIM and Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Information technologies already have a key role in pharmaceutical research and development (R&D), but achieving substantial advances in their use and effectiveness will depend on overcoming current challenges in sharing, integrating and jointly analysing the range of data generated at different stages of the R&D process.

Indexed as

Knowledge ManagementCooperative BehaviorDrug IndustryHumansInformation ManagementResearchTechnology, Pharmaceutical

Identifiers

PMID24687050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.